动脉介入健择、顺铂治疗肺癌的临床研究  

Application Study of Gemcitabine and Cisplatin in Interventional Therapy on Advanced NSCLC

作　　者：李威[1] 李大伟[1] 

机构地区：[1]黑龙江省医院介入治疗科,哈尔滨150036

出　　处：《中国肺癌杂志》2009年第6期535-536,共2页Chinese Journal of Lung Cancer

摘　　要：背景与目的探讨健择加顺铂通过支气管动脉灌注区域化疗,了解治疗中、晚期非小细胞肺癌的临床效果及不良反应。方法采用seldinger技术,对38例中、晚期非小细胞肺癌进行选择或超选择性灌注健择加顺铂,观察疗效。结果本组38例经支气管动脉灌注健择加顺铂,人均2-3个周期,经介入前后影像学、实验室检查对比,(CR+PR)总有效率达到84.2%。不良反应主要表现在血液学方面。结论健择加顺铂通过介入的方法治疗非小细胞肺癌的近期临床效果佳,远期效果尚待观察。Background and objective To study clinical effection and side effection ofgemcitabine and cisplatin to advanced NSCLC through bronchial artery. Methods Using Seldinger skill treat advanced NSCLC by local artery. Results Tested group effection（CR＋PR）was 84.2%.Side effections came from blood region. Conclusion It has a good effection that gemcitabine and cisplatin cure advanced NSCLC by interventional skill.

关 键 词：健择 肺癌 介入 

分 类 号：R734.2[医药卫生—肿瘤]